drugset / Trial / NCT00064415

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

NCT00064415

Phase 3 Completed 799 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD

Timeline

Start
2002-06
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Arformoterol Small molecule 50 ug Inhaled
Comparator Salmeterol Other / unclassified 42 ug Inhaled